We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The federal government has granted two contracts worth more than $2 billion as part of Operation Warp Speed — $1.6 billion to Novavax to manufacture and develop its COVID-19 vaccine candidate, and $450 million to Regeneron Pharmaceuticals to manufacture and supply its antibody cocktail to treat COVID-19. Read More
The European Medicines Agency (EMA) has issued a proposed five-year pharmaceutical regulatory plan with six areas of focus including improvements in the drug supply chain. Read More
Emergent BioSolutions has secured a five-year agreement with Johnson and Johnson to manufacture drug substances for J&J’s COVID-19 vaccine candidate. Read More
While several hydroxychloroquine trials in COVID-19 patients have been shuttered, a large study led by Michigan’s Henry Ford Health System (HFHS) has found that the antimalarial drug significantly cut death rates in hospitalized patients and could still hold promise as a COVID-19 treatment. Read More
Regeneron Pharmaceuticals has begun a phase 3 clinical trial in the U.S. of its antibody cocktail REGN-COV2 for the prevention of COVID-19 infections. Read More